Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sotatercept - Acceleron Pharma/Celgene Corporation

Drug Profile

Sotatercept - Acceleron Pharma/Celgene Corporation

Alternative Names: ACE-011; ACTRIIA-Fc; RAP-011

Latest Information Update: 24 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Acceleron Pharma
  • Developer Acceleron Pharma; Celgene Corporation; Indiana University; North Shore-Long Island Jewish Health System; University of Texas M. D. Anderson Cancer Center
  • Class Antianaemics; Antihypertensives; Osteoporosis therapies; Recombinant fusion proteins
  • Mechanism of Action Activin inhibitors; Bone resorption factor inhibitors; Haemoglobin stimulants; Osteoblast inhibitors; Osteoclast stimulants; Osteogenesis stimulants; Transforming growth factor beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Beta-thalassaemia; Pulmonary arterial hypertension; Anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Anaemia; Beta-thalassaemia; Myelofibrosis; Pulmonary arterial hypertension; Renal osteodystrophy; Vascular calcification
  • Phase I/II Diamond-Blackfan syndrome
  • Clinical Phase Unknown Myelodysplastic syndromes
  • No development reported Cancer metastases; Chemotherapy-induced anaemia; Postmenopausal osteoporosis; Sickle cell anaemia

Most Recent Events

  • 09 Sep 2019 Sotatercept received Orphan Drug status for Pulmonary arterial hypertension in USA
  • 26 Jun 2019 Acceleron Pharma completes enrolment in the phase II PULSAR trial for Pulmonary arterial hypertension in USA, Australia, Israel, Germany and Spain (SC) (NCT03496207)
  • 17 May 2019 Preclinical pharmacodynamics data in Pulmonary arterial hypertension presented at the 115th International Conference of the American Thoracic Society (ATS-2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top